CN Stock MarketDetailed Quotes

688266 Suzhou Zelgen Biopharmaceuticals

Watchlist
  • 68.16
  • +1.80+2.71%
Market Closed Nov 12 15:00 CST
18.04BMarket Cap-103429P/E (TTM)

Suzhou Zelgen Biopharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Suzhou Zelgen Biopharmaceuticals Q3 2024 Earnings Date

Currency：CNYOct 26, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
--
143.42M
--
+130.67%
Net Income
--
-32.12M
--
+65.65%
Analyst Rating
Strong Buy

Nov 12, 2024

Suzhou Zelgen Biopharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/FY-- / 1.189B--
--2024/FY-- / 614.565M--
--2023/FY386.439M / 429.000M--
--2021/FY190.361M / 208.000M--
--2020/FY27.661M / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/FY-- / 1.189B--
--2024/FY-- / 614.565M--
--2023/FY386.439M / 429.000M--
--2021/FY190.361M / 208.000M--
--2020/FY27.661M / 0.000--

Unlock Free Earnings Estimates

Suzhou Zelgen Biopharmaceuticals Earnings Reports

  • Zejing Pharmaceutical Report for the Third Quarter of 2024

    Oct 26 00:00

  • Zejing Pharmaceuticals Semi-Annual Report 2024

    Aug 24 00:00

  • Summary of Zhejiang Jing Pharmaceutical's 2024 interim report

    Aug 24 00:00

  • Summary of Zejing Pharmaceutical's 2023 Annual Report

    Apr 20 00:00

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 12, 2024

    Strong Buy

    • Strong Buy

      82.35%

    • Buy

      17.65%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Latest Price
    % Chg

    No Data